PIP and colonic neoplasm: According to MTS and RTCA, the lipid nanocarriers induced advanced LoVo colon tumor cell death (e.g., 15.73% ± 0.82 cell viability and 21.95% ± 1.06 for 400 mg/mL NLC-Pip and NLC-Pip–BSA, respectively), comparable and even more prominent than those produced by the chemotherapy drug, Cisplatin.